Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
A phase 3 trial of Trastuzumab deruxtecan in endometrial cancer, run by Daiichi Sankyo, now recruiting.
Overview
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer is a phase 3 interventional study registered as NCT07022483 by Daiichi Sankyo, with 710 participants planned, started 2025-09-30 and due to reach its primary completion in 2032-03-23. Interventions recorded: Trastuzumab Deruxtecan, Chemotherapy. Conditions listed: Endometrial Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
Shares Daiichi Sankyo, Trastuzumab deruxtecan.
- TrialStudy of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-
Shares Daiichi Sankyo, Trastuzumab deruxtecan.
- TrialTrastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Shares Daiichi Sankyo, Trastuzumab deruxtecan.
- TrialA Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
Shares Daiichi Sankyo, Trastuzumab deruxtecan.
- TrialStudy of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Shares Daiichi Sankyo, Trastuzumab deruxtecan.
- PersonNoboru Yamamoto
Shares Daiichi Sankyo, Trastuzumab deruxtecan.
- TrialStudy of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Shares Daiichi Sankyo, Trastuzumab deruxtecan.
- TrialA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Shares Daiichi Sankyo, Endometrial cancer.